title: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'.
authors.forename: Carlo
authors.initials: C
authors.lastname: Gambacorti-Passerini
authors.forename: Carlo
authors.initials: C
authors.lastname: Gambacorti
authors.forename: Lucia
authors.initials: L
authors.lastname: Tornaghi
authors.forename: Anna
authors.initials: A
authors.lastname: Franceschino
authors.forename: Rocco
authors.initials: R
authors.lastname: Piazza
authors.forename: Gianmarco
authors.initials: G
authors.lastname: Corneo
authors.forename: Enrico
authors.initials: E
authors.lastname: Pogliani
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D006333:Heart Failure / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate